Belzutifan is approved by USFDA for advanced renal cell carcinoma

The Food and Drug Administration granted approval for belzutifan (Welireg, Merck & Co., Inc.) on December 14, 2023, for patients with advanced renal cell carcinoma (RCC) who have previously received a programmed death recepto..

NCT03142334, Pembrolizumab, renal cell carcinoma

Pembrolizumab is approved for adjuvant treatment of renal cell carcinoma

Jan 2022: Pembrolizumab (Keytruda, Merck) has been approved by the Food and Drug Administration for the adjuvant treatment of patients with renal cell carcinoma (RCC) who are at intermediate-high or high risk of recurrence after ..

KEYTRUDA, Lenvatinib, Lenvatinib plus pembrolizumab, Lenvima, Merck, renal cell carcinoma

The FDA has approved the combination of lenvatinib and pembrolizumab for advanced renal cell carcinoma

August 2021: The combination of lenvatinib (Lenvima, Eisai) and pembrolizumab (Keytruda, Merck) has been approved by the Food and Drug Administration for the first-line treatment of adult patients with advanced renal cell carcinom..

AVEO Pharmaceuticals, Fotivda, kinase inhibitor, refractory advanced renal cell carcinoma, renal cell carcinoma, tivozanib

Tivozanib has been approved by the FDA for the treatment of relapsed or refractory advanced renal cell carcinoma

August 2021: Tivozanib (Fotivda, AVEO Pharmaceuticals, Inc.), a kinase inhibitor, has been approved by the FDA for adult patients with relapsed or refractory advanced renal cell carcinoma (RCC) after two or more prior systemic the..

8 major causes of kidney cancer

Many patients with kidney cancer do not know why they have this disease, meaning the causes of kidney cancer are relatively unknown. After the examination, they will be very surprised. Some even feel that the kidney is not a probl..